Abstract
Dysregulation of the complement system has been linked to the pathogenesis of hypertension. However, whether genetic changes of complement factor H (CFH) and its related genes are associated with hypertension is unknown. We genotyped three SNPs in the CFH gene cluster—rs1061170 (Y402H), rs2274700 (A473A), and rs7542235 (CFHR1-3Δ)—and tested for their associations with blood pressure and hypertension risk in a population-based cohort of 3,210 unrelated Chinese Hans (50-70 years of age). We found that rs2274700 and rs7542235 were significantly associated with diastolic blood pressure (DBP) and systolic blood pressure (SBP). Notably, the associations were significant only in individuals with low C-reactive protein (CRP) levels (<2.0 mg/l). These results suggest that genetic variations in CFH and its related genes may contribute to hypertension risk in the Chinese Han population.
Introduction
Hypertension is increasingly recognized as a multifactorial inflammatory disease. While the complement system—a key component of innate immunity—is known to be involved in vascular health, the specific genetic drivers remain unclear. Complement component 3 (C3) levels are often elevated in hypertensive patients, prompting investigation into the genes responsible for regulating C3. This study focuses on the CFH gene cluster and its related genes (CFHR1–5) to determine if genetic variants previously linked to age-related macular degeneration (AMD) also play a role in systemic blood pressure regulation within a Chinese Han population.
Methods
The study utilized a population-based cohort of 3,210 unrelated Chinese Hans (ages 50–70) from Beijing and Shanghai.
Genotyping and Phenotyping
Researchers targeted three specific Single Nucleotide Polymorphisms (SNPs) in the CFH gene cluster:
- rs1061170 (Y402H)
- rs2274700 (A473A)
- rs7542235 (tagging the CFHR1-3Δ deletion)
Blood pressure was measured using standardized protocols. For participants already taking anti-hypertensive medications, adjustments were made by adding 10 mmHg to SBP and 5 mmHg to DBP to account for treatment effects.
Statistical Analysis
Generalized linear regression and logistic regression models were used to test associations, adjusting for age, sex, and BMI. A key component of the analysis was an interaction test to determine if plasma C-reactive protein (CRP) levels, a marker of systemic inflammation, modified the genetic risk.
Results
Genetic Associations with Blood Pressure
The study found that risk alleles for rs2274700 and rs7542235 were associated with significant increases in blood pressure metrics:
- Diastolic Blood Pressure (DBP): Increase of 0.632–1.431 mmHg (P ≤ 0.038).
- Systolic Blood Pressure (SBP): Increase of 1.567–4.445 mmHg (P ≤ 0.008).
- Hypertension Risk: Carrying the rs2274700 (A473A) variant increased the overall risk of hypertension by approximately 17.5% (OR: 1.175, P = 0.048).
Interestingly, rs1061170 (Y402H), which is a major risk factor for AMD, showed no significant association with blood pressure in this cohort (P ≥ 0.259). This suggests that different functional domains of the CFH protein may have highly specialized roles in different disease states.
The CRP Interaction Paradox
The most striking finding was that the genetic association with blood pressure was only significant in individuals with low systemic inflammation (CRP < 2.0 mg/l).
- Low CRP Group: The association between rs2274700 and SBP was highly significant (P = 8 × 10⁻⁵).
- High CRP Group: The genetic signal was non-existent (P ≥ 0.0807).
This interaction (P for interaction ≤ 0.0467) suggests that CFH variants may be a primary driver of "low-grade" inflammation that leads to hypertension, but their specific effect is overwhelmed or masked in high-inflammatory states. Structurally, rs2274700 is located at the CFH-CRP binding site, providing a biological rationale for this link.
Discussion
These findings suggest that genetic variations in the CFH gene cluster contribute to hypertension risk in the Chinese Han population, particularly in the absence of high systemic inflammation.
Limitations and Future Directions
As a cross-sectional cohort study, these results identify associations but do not definitively prove causation. Furthermore, allele frequencies vary significantly across ethnicities; for instance, the Y402H variant is far more common in European populations than in Chinese populations, meaning these results may not generalize globally. Direct functional studies are required to confirm how these mutations alter CFH activity in the vasculature. Future work should focus on validating these gene-CRP interactions in larger, independent cohorts to assess their potential for clinical risk prediction.
Summary updated